Therapeutic options in Charcot-Marie-Tooth diseases

Expert Review of Neurotherapeutics

Volumn 15, Issue 4, 2015, Pages 355-366

  Mathis, Stéphane ^a   Magy, Laurent ^b   Vallat, Jean Michel ^b  

^a POITIERS UNIVERSITY HOSPITAL   (France)

^b LIMOGES UNIVERSITY HOSPITAL   (France)

Author keywords

animal model; Charcot Marie Tooth disease; CMT; dHMN; GJB1; MPZ; myelin; PMP22

Indexed keywords

NEUROTROPHIC FACTOR;

AUTOPHAGY; BRAIN CORTEX; DAILY LIFE ACTIVITY; DIET SUPPLEMENTATION; FOOT MALFORMATION; GIANT AXONAL NEUROPATHY; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; IMMUNOMODULATION; LOWER URINARY TRACT SYMPTOM; MUSCLE ISOMETRIC CONTRACTION; MUSCLE WEAKNESS; NERVE REGENERATION; NEXT GENERATION SEQUENCING; NONHUMAN; PHENOTYPE; PHYSICAL DISABILITY; QUALITY OF LIFE; RESISTANCE TRAINING; REVIEW; ANIMAL; CHARCOT-MARIE-TOOTH DISEASE; CLINICAL DECISION MAKING; DISEASE MANAGEMENT; DISEASE MODEL; GENETICS; OUTCOME ASSESSMENT; PATHOLOGY; PERIPHERAL NERVOUS SYSTEM;

ANIMALS; CHARCOT-MARIE-TOOTH DISEASE; CLINICAL DECISION-MAKING; DISEASE MANAGEMENT; DISEASE MODELS, ANIMAL; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PERIPHERAL NERVOUS SYSTEM;

EID: 84925864114     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.2015.1017471     Document Type: Review

References (119)

1. Braathen GJ, Sand JC, Lobato A, et al.Genetic epidemiology of Charcot-Marie-Tooth in the general population.Eur J Neurol 2011; 18(1): 39-48
2. Charcot JM, Marie P.Sur une forme particulière d'atrophie musculaire progressive, souvent familiale, débutant par les pieds et les jambes et atteignant plus tard les mains.Rev Méd 1886; 6: 97-138
3. Tooth HH.The peroneal type of progressive muscular atrophy.H.K.Lewis; London: 1886
4. Lupski JR, de Oca-Luna RM, Slaugenhaupt S, et al.DNA duplication associated with Charcot-Marie-Tooth disease type 1A.Cell 1991; 66(2): 219-32
5. Raeymaekers P, Timmerman V, Nelis E, et al.Duplication in chromosome 17p11.2 in Charcot-Marie-Tooth neuropathy type 1a (CMT 1a).The HMSN Collaborative Research Group.Neuromuscul Disord 1991; 1(2): 93-7
6. Vallat JM, Mathis S, Funalot B.The various Charcot-Marie-Tooth diseases.Curr Opin Neurol 2013; 26(5): 473-80
7. Bouhy D, Timmerman V.Animal models and therapeutic prospects for Charcot-Marie-Tooth disease.Ann Neurol 2013; 74(3): 391-6
8. Bombelli F, Stojkovic T, Dubourg O, et al.Charcot-Marie-Tooth disease type 2A: from typical to rare phenotypic and genotypic features.JAMA Neurol 2014; 71(8): 1036-42
9. Available from: www.molgen.ua.ac.be/.CMTMutations
10. Saporta AS, Sottile SL, Miller LJ, et al.Charcot-Marie-Tooth disease subtypes and genetic testing strategies.Ann Neurol 2011; 69(1): 22-33
11. Rossor AM, Polke JM, Houlden H, et al.Clinical implications of genetic advances in Charcot-Marie-Tooth disease.Nat Rev Neurol 2013; 9(10): 562-71
12. Shy ME, Lupski JR, Chance PF, et al.Hereditary motor and sensory neuropathies: an overview of clinical, genetic, electrophysiologic, and pathologic features.In: Dyck P, Thomas P, editors.Peripheral neuropathy.Elsevier Saunders; Philadelphia: 2005.p.1623-58
13. Harding AE, Thomas PK.Genetic aspects of hereditary motor and sensory neuropathy (types I and II).J Med Genet 1980; 17(5): 329-36
14. Souayah N, Seltzer WK, Brannagan TH, et al.Rare myelin protein zero sequence variant in late onset CMT1B.J Neurol Sci 2007; 263(1-2): 177-9
15. Dejerine J, Sottas J.Sur la névrite interstitielle, hypertrophique et progressive de l'enfant C r soc biol 1893; 45: 63-96
16. Wilmshurst JM, Ouvrier R.Hereditary peripheral neuropathies of childhood: an overview for clinicians.Neuromuscul Disord 2011; 21(11): 763-75
17. Scherer SS, Wrabetz L.Molecular mechanisms of inherited demyelinating neuropathies.Glia 2008; 56(14): 1578-89
18. Warner LE, Hilz MJ, Appel SH, et al.Clinical phenotypes of different MPZ (P0) mutations may include Charcot-Marie-Tooth type 1B, Dejerine-Sottas, and congenital hypomyelination.Neuron 1996; 17(3): 451-60
19. Vallat JM.Dominantly inherited peripheral neuropathies.J Neuropathol Exp Neurol 2003; 62(7): 699-714
20. Wechsler W.The development and structure of peripheral nerves in vertebrate.In: Vinken RJ, Bryuyn GW, editors.Diseases of nerves (Part I).Elsevier North-Holland; New York: 1970.p.1-39
21. Vallat JM, Tazir M, Magdelaine C, et al.Autosomal-recessive Charcot-Marie-Tooth diseases.J Neuropathol Exp Neurol 2005; 64(5): 363-70
22. Verhamme C, van Schaik IN, Koelman JH, et al.The natural history of Charcot-Marie-Tooth type 1A in adults: a 5-year follow-up study.Brain 2009; 132(12): 3252-62
23. Reilly MM, Shy ME, Muntoni F, et al.168th ENMC International Workshop: outcome measures and clinical trials in Charcot-Marie-Tooth disease (CMT).Neuromuscul Disord 2010.20(12): 839-46
24. Sames L, Moore A, Arnold R, et al.Recommendations to enable drug development for inherited neuropathies: charcot-Marie-Tooth and Giant Axonal Neuropathy.F1000Res 2014; 3: 83
25. Hogrel JY, Payan CA, Ollivier G, et al.Development of a French isometric strength normative database for adults using quantitative muscle testing.Arch Phys Med Rehabil 2007; 88(10): 1289-97
26. de Lattre C, Payan C, Vuillerot C, et al.Motor function measure: validation of a short form for young children with neuromuscular diseases.Arch Phys Med Rehabil 2013; 94(11): 2218-26
27. Mannil M, Solari A, Leha A, et al.Selected items from the Charcot-Marie-Tooth (CMT) Neuropathy Score and secondary clinical outcome measures serve as sensitive clinical markers of disease severity in CMT1A patients.Neuromuscul Disord 2014; 24(11): 1003-17
28. Shy ME, Blake J, Krajewski K, et al.Reliability and validity of the CMT neuropathy score as a measure of disability.Neurology 2005; 64(7): 1209-14
29. Komyathy K, Neal S, Feely S, et al.Anterior tibialis CMAP amplitude correlations with impairment in CMT1A.Muscle Nerve 2013; 47(4): 493-6
30. Murphy SM, Herrmann DN, McDermott MP, et al.Reliability of the CMT neuropathy score (second version) in Charcot-Marie-Tooth disease.J Peripher Nerv Syst 2011; 16(3): 191-8
31. Burns J, Ouvrier R, Estilow T, et al.Validation of the Charcot-Marie-Tooth disease pediatric scale as an outcome measure of disability.Ann Neurol 2012; 71(5): 642-52
32. Solari A, Laura M, Salsano E, et al.Reliability of clinical outcome measures in Charcot-Marie-Tooth disease.Neuromuscul Disord 2008; 18(1): 19-26
33. Chetlin RD, Gutmann L, Tarnopolsky M, et al.Resistance training effectiveness in patients with Charcot-Marie-Tooth disease: recommendations for exercise prescription.Arch Phys Med Rehabil 2004; 85(8): 1217-23
34. Piscosquito G, Reilly MM, Schenone A, et al.Is overwork weakness relevant in Charcot-Marie-Tooth disease?.J Neurol Neurosurg Psychiatry 2014; 85(12): 1354-8
35. Lencioni T, Rabuffetti M, Piscosquito G, et al.Postural stabilization and balance assessment in Charcot-Marie-Tooth 1A subjects.Gait Posture 2014; 40(4): 481-6
36. Dufek JS, Neumann ES, Hawkins MC, et al.Functional and dynamic response characteristics of a custom composite ankle foot orthosis for Charcot-Marie-Tooth patients.Gait Posture 2014; 39(1): 308-13
37. Padua L, Pazzaglia C, Schenone A, et al.Rehabilitation for Charcot Marie tooth: a survey study of patients and familiar/.caregiver perspective and perception of efficacy and needs.Eur J Phys Rehabil Med 2014; 50(1): 25-30
38. Barton T, Winson I.Joint sparing correction of cavovarus feet in Charcot-Marie-Tooth disease: what are the limits?.Foot Ankle Clin 2013; 18(4): 673-88
39. Tiffreau V, Allart E, Dangleterre C, et al.Botulinum toxin treatment of pes cavovarus in a child suffering from autosomal recessive axonal Charcot-Marie-Tooth neuropathy (AR-CMT2).Eur J Phys Rehabil Med 2014; In press
40. Estilow T, Kozin SH, Glanzman AM, et al.Flexor digitorum superficialis opposition tendon transfer improves hand function in children with Charcot-Marie-Tooth disease: case series.Neuromuscul Disord 2012; 22(12): 1090-5
41. Walker JL, Nelson KR, Heavilon JA, et al.Hip abnormalities in children with Charcot-Marie-Tooth disease.J Pediatr Orthop 1994; 14(1): 54-9
42. Novais EN, Bixby SD, Rennick J, et al.Hip dysplasia is more severe in Charcot-Marie-Tooth disease than in developmental dysplasia of the hip.Clin Orthop Relat Res 2013; 472(2): 665-73
43. Kalkman JS, Schillings ML, van der Werf SP, et al.Experienced fatigue in facioscapulohumeral dystrophy, myotonic dystrophy, and HMSN-I.J Neurol Neurosurg Psychiatry 2005; 76(10): 1406-9
44. Ramdharry GM, Thornhill A, Mein G, et al.Exploring the experience of fatigue in people with Charcot-Marie-Tooth disease.Neuromuscul Disord 2012; 22(Suppl 3): S208-13
45. Carter GT, Han JJ, Mayadev A, et al.Modafinil reduces fatigue in Charcot-Marie-Tooth disease type 1A: a case series.Am J Hosp Palliat Care 2006; 23(5): 412-16
46. Krhut J, Mazanec R, Seeman P, et al.Lower urinary tract functions in a series of Charcot-Marie-Tooth neuropathy patients.Acta Neurol Scand 2013; 129(5): 319-24
47. Ribiere C, Bernardin M, Sacconi S, et al.Pain assessment in Charcot-Marie-Tooth (CMT) disease.Ann Phys Rehabil Med 2012; 55(3): 160-73
48. Cordeiro JL, Marques W, Hallak JE, et al.Charcot-Marie-Tooth disease, psychiatric indicators and quality of life: a systematic review.ASN Neuro 2014; 6(3): 185-92
49. Boentert M, Knop K, Schuhmacher C, et al.Young P.Sleep disorders in Charcot-Marie-Tooth disease type 1.J Neurol Neurosurg Psychiatry 2014; 85(3): 319-25
50. Aboussouan LS, Lewis RA, Shy ME.Disorders of pulmonary function, sleep, and the upper airway in Charcot-Marie-Tooth disease.Lung 2007; 185(1): 1-7
51. Jeong NY, Shin YH, Jung J.Neuropathic pain in hereditary peripheral neuropathy.J Exerc Rehabil 2013; 9(4): 397-9
52. Weimer LH, Podwall D.Medication-induced exacerbation of neuropathy in Charcot Marie Tooth disease.J Neurol Sci 2006; 242(1-2): 47-54
53. Robertson AM, Perea J, McGuigan A, et al.Comparison of a new pmp22 transgenic mouse line with other mouse models and human patients with CMT1A.J Anat 2002; 200(4): 377-90
54. Huxley C, Passage E, Manson A, et al.Construction of a mouse model of Charcot-Marie-Tooth disease type 1A by pronuclear injection of human YAC DNA.Hum Mol Genet 1996; 5(5): 563-9
55. Huxley C, Passage E, Robertson AM, et al.Correlation between varying levels of PMP22 expression and the degree of demyelination and reduction in nerve conduction velocity in transgenic mice.Hum Mol Genet 1998; 7(3): 449-58
56. Magyar JP, Martini R, Ruelicke T, et al.Impaired differentiation of Schwann cells in transgenic mice with increased PMP22 gene dosage.J Neurosci 1996; 16(17): 5351-60
57. Sereda M, Griffiths I, Puhlhofer A, et al.A transgenic rat model of Charcot-Marie-Tooth disease.Neuron 1996; 16(5): 1049-60
58. Fledrich R, Stassart RM, Sereda MW.Murine therapeutic models for Charcot-Marie-Tooth (CMT) disease.Br Med Bull 2012; 102: 89-113
59. Suter U, Welcher AA, Ozcelik T, et al.Trembler mouse carries a point mutation in a myelin gene.Nature 1992; 356(6366): 241-4
60. Suter U, Moskow JJ, Welcher AA, et al.A leucine-To-proline mutation in the putative first transmembrane domain of the 22-kDa peripheral myelin protein in the trembler-J mouse.Proc Natl Acad Sci USA 1992; 89(10): 4382-6
61. Sereda MW, Meyer zu Horste G, Suter U, et al.Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A).Nat Med 2003; 9(12): 1533-7
62. Passage E, Norreel JC, Noack-Fraissignes P, et al.Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease.Nat Med 2004; 10(4): 396-401
63. Sahenk Z, Galloway G, Clark KR, et al.AAV1.NT-3 gene therapy for Charcot-Marie-Tooth neuropathy.Mol Ther 2014; 22(3): 511-21
64. Khajavi M, Shiga K, Wiszniewski W, et al.Oral curcumin mitigates the clinical and neuropathologic phenotype of the Trembler-J mouse: a potential therapy for inherited neuropathy.Am J Hum Genet 2007; 81(3): 438-53
65. Cochrane S, Bergoffen J, Fairweather ND, et al.X linked Charcot-Marie-Tooth disease (CMTX1): a study of 15 families with 12 highly informative polymorphisms.J Med Genet 1994; 31(3): 193-6
66. Kleopa KA, Scherer SS.Molecular genetics of X-linked Charcot-Marie-Tooth disease.Neuromolecular Med 2006; 8(1-2): 107-22
67. Jeng LJ, Balice-Gordon RJ, Messing A, et al.The effects of a dominant connexin32 mutant in myelinating Schwann cells.Mol Cell Neurosci 2006; 32(3): 283-98
68. Quarles RH, Macklin WB, Morell P.Myelin formation, structure and biochemistry.In: Brady S, Siegel G, Albers W, Price D, editors.Basic neurochemistry: molecular, cellular and medical aspects.Lippincott-Raven; Philadelphia: 2006.p.51-71
69. Wrabetz L, D'Antonio M, Pennuto M, et al.Different intracellular pathomechanisms produce diverse Myelin Protein Zero neuropathies in transgenic mice.J Neurosci 2006; 26(8): 2358-68
70. Martini R, Zielasek J, Toyka KV, et al.Protein zero (P0)-deficient mice show myelin degeneration in peripheral nerves characteristic of inherited human neuropathies.Nat Genet 1995; 11(3): 281-6
71. D'Antonio M, Musner N, Scapin C, et al.Resetting translational homeostasis restores myelination in Charcot-Marie-Tooth disease type 1B mice.J Exp Med 2013; 210(4): 821-38
72. Ajroud-Driss S, Deng HX, Siddique T.Recent advances in the genetics of hereditary axonal sensory-motor neuropathies type 2.Curr Neurol Neurosci Rep 2011; 11(3): 262-73
73. Lee MK, Marszalek JR, Cleveland DW.A mutant neurofilament subunit causes massive, selective motor neuron death: implications for the pathogenesis of human motor neuron disease.Neuron 1994; 13(4): 975-88
74. d'Ydewalle C, Krishnan J, Chiheb DM, et al.HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot-Marie-Tooth disease.Nat Med 2011; 17(8): 968-74
75. Cotter L, Ozcelik M, Jacob C, et al.Dlg1-PTEN interaction regulates myelin thickness to prevent damaging peripheral nerve overmyelination.Science 2010; 328(5984): 1415-18
76. Bonneick S, Boentert M, Berger P, et al.An animal model for Charcot-Marie-Tooth disease type 4B1.Hum Mol Genet 2005; 14(23): 3685-95
77. Storkebaum E, Leitao-Goncalves R, Godenschwege T, et al.Dominant mutations in the tyrosyl-TRNA synthetase gene recapitulate in Drosophila features of human Charcot-Marie-Tooth neuropathy.Proc Natl Acad Sci USA 2009; 106(28): 11782-7
78. Young P, De Jonghe P, Stogbauer F, et al.Treatment for Charcot-Marie-Tooth disease.Cochrane Database Syst Rev 2008(1): CD006052
79. Burns J, Ouvrier RA, Yiu EM, et al.Ascorbic acid for Charcot-Marie-Tooth disease type 1A in children: a randomised, double-blind, placebo-controlled, safety and efficacy trial.Lancet Neurol 2009; 8(6): 537-44
80. Micallef J, Attarian S, Dubourg O, et al.Effect of ascorbic acid in patients with Charcot-Marie-Tooth disease type 1A: a multicentre, randomised, double-blind, placebo-controlled trial.Lancet Neurol 2009; 8(12): 1103-10
81. Verhamme C, de Haan RJ, Vermeulen M, et al.Oral high dose ascorbic acid treatment for one year in young CMT1A patients: a randomised, double-blind, placebo-controlled phase II trial.BMC Med 2009; 7: 70
82. Pareyson D, Reilly MM, Schenone A, et al.Ascorbic acid in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL and CMTTRAUK): a double-blind randomised trial.Lancet Neurol 2011; 10(4): 320-8
83. Gess B, Rohr D, Young P.Ascorbic acid and sodium-dependent vitamin C transporters in the peripheral nervous system: from basic science to clinical trials.Antioxid Redox Signal 2013; 19(17): 2105-14
84. Visioli F, Reilly MM, Rimoldi M, et al.Vitamin C and Charcot-Marie-Tooth 1A: pharmacokinetic considerations.PharmaNutrition 2013; 1(1): 10-12
85. Koenig HL, Schumacher M, Ferzaz B, et al.Progesterone synthesis and myelin formation by Schwann cells.Science 1995; 268(5216): 1500-3
86. Meyer zu Horste G, Prukop T, Liebetanz D, et al.Antiprogesterone therapy uncouples axonal loss from demyelination in a transgenic rat model of CMT1A neuropathy.Ann Neurol 2007; 61(1): 61-72
87. Attarian S, Vallat JM, Magy L, et al.An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A.Orphanet J Rare Dis 2014; 9(1): 199
88. Schadt EE, Friend SH, Shaywitz DA.A network view of disease and compound screening.Nat Rev Drug Discov 2009; 8(4): 286-95
89. Gupta SC, Patchva S, Aggarwal BB.Therapeutic roles of curcumin: lessons learned from clinical trials.AAPS J 2013; 15(1): 195-218
90. Epstein J, Sanderson IR, Macdonald TT.Curcumin as a therapeutic agent: the evidence from in vitro, animal and human studies.Br J Nutr 2010; 103(11): 1545-57
91. Patzko A, Bai Y, Saporta MA, et al.Curcumin derivatives promote Schwann cell differentiation and improve neuropathy in R98C CMT1B mice.Brain 2012; 135(12): 3551-66
92. Burns J, Joseph PD, Rose KJ, et al.Effect of oral curcumin on Dejerine-Sottas disease.Pediatr Neurol 2009; 41(4): 305-8
93. Bagriyanik HA, Ersoy N, Cetinkaya C, et al.The effects of resveratrol on chronic constriction injury of sciatic nerve in rats.Neurosci Lett 2014; 561: 123-7
94. Yuan H, Zhang J, Liu H, Li Z.The protective effects of resveratrol on Schwann cells with toxicity induced by ethanol in vitro.Neurochem Int 2013; 63(3): 146-53
95. Jerath NU, Shy ME.Hereditary motor and sensory neuropathies: understanding molecular pathogenesis could lead to future treatment strategies.Biochim Biophys Acta 2014.[Epub ahead of print
96. Cheng F, Lienlaf M, Wang HW, et al.A novel role for histone deacetylase 6 in the regulation of the tolerogenic STAT3/IL-10 pathway in APCs.J Immunol 2014; 193(6): 2850-62
97. Gentil BJ, Mushynski WE, Durham HD.Heterogeneity in the properties of NEFL mutants causing Charcot-Marie-Tooth disease results in differential effects on neurofilament assembly and susceptibility to intervention by the chaperone-inducer, celastrol.Int J Biochem Cell Biol 2013; 45(7): 1499-508
98. Patapoutian A, Reichardt LF.Trk receptors: mediators of neurotrophin action.Curr Opin Neurobiol 2001; 11(3): 272-80
99. Sahenk Z, Nagaraja HN, McCracken BS, et al.NT-3 promotes nerve regeneration and sensory improvement in CMT1A mouse models and in patients.Neurology 2005; 65(5): 681-9
100. Chong ZZ, Shang YC, Wang S, et al.Shedding new light on neurodegenerative diseases through the mammalian target of rapamycin.Prog Neurobiol 2012; 99(2): 128-48
101. Rangaraju S, Verrier JD, Madorsky I, et al.Rapamycin activates autophagy and improves myelination in explant cultures from neuropathic mice.J Neurosci 2010; 30(34): 11388-97
102. Nicks J, Lee S, Harris A, et al.Rapamycin improves peripheral nerve myelination while it fails to benefit neuromuscular performance in neuropathic mice.Neurobiol Dis 2014; 70: 224-36
103. Nobbio L, Visigalli D, Mannino E, et al.The diadenosine homodinucleotide P18 improves in vitro myelination in experimental Charcot-Marie-Tooth type 1A.J Cell Biochem 2014; 115(1): 161-7
104. Ginsberg L, Malik O, Kenton AR, et al.Coexistent hereditary and inflammatory neuropathy.Brain 2004; 127(1): 193-202
105. Marques W Jr, Funayama CA, Secchin JB, et al.Coexistence of two chronic neuropathies in a young child: charcot-Marie-Tooth disease type 1A and chronic inflammatory demyelinating polyneuropathy.Muscle Nerve 2010; 42(4): 598-600
106. Falls DL.Neuregulins: functions, forms, and signaling strategies.Exp Cell Res 2003; 284(1): 14-30
107. Michailov GV, Sereda MW, Brinkmann BG, et al.Axonal neuregulin-1 regulates myelin sheath thickness.Science 2004; 304(5671): 700-3
108. Fledrich R, Stassart RM, Klink A, et al.Soluble neuregulin-1 modulates disease pathogenesis in rodent models of Charcot-Marie-Tooth disease 1A.Nat Med 2014; 20(9): 1055-61
109. Falls DL.Neuregulins and the neuromuscular system: 10 years of answers and questions.J Neurocytol 2003; 32(5-8): 619-47
110. Nave KA, Salzer JL.Axonal regulation of myelination by neuregulin 1.Curr Opin Neurobiol 2006; 16(5): 492-500
111. Tu Y, Luo R, Li X, et al.Hypermyelination and overexpression of neuregulin-1 in thoracic sympathetic nerves in patients with primary palmar hyperhidrosis.J Clin Neurosci 2012; 19(12): 1651-3
112. Taveggia C, Zanazzi G, Petrylak A, et al.Neuregulin-1 type III determines the ensheathment fate of axons.Neuron 2005; 47(5): 681-94
113. Gouttenoire EA, Lupo V, Calpena E, et al.Sh3tc2 deficiency affects neuregulin-1/ErbB signaling.Glia 2013; 61(7): 1041-51
114. Moldovan M, Pinchenko V, Dmytriyeva O, et al.Peptide mimetic of the S100A4 protein modulates peripheral nerve regeneration and attenuates the progression of neuropathy in myelin protein P0 null mice.Mol Med 2013; 19: 43-53
115. Shi TJ, Zhang MD, Zeberg H, et al.Coenzyme Q10 prevents peripheral neuropathy and attenuates neuron loss in the db-/db- mouse, a type 2 diabetes model.Proc Natl Acad Sci USA 2013; 110(2): 690-5
116. Takahashi R, Ikeda T, Hamaguchi A, et al.Coenzyme Q10 therapy in hereditary motor sensory neuropathy type VI with novel mitofusin 2 mutation.Intern Med 2012; 51(7): 791-3
117. Williams LL, O'Dougherty MM, Wright FS, et al.Dietary essential fatty acids, vitamin E, and Charcot-Marie-Tooth disease.Neurology 1986; 36(9): 1200-5
118. Smith CA, Chetlin RD, Gutmann L, et al.Effects of exercise and creatine on myosin heavy chain isoform composition in patients with Charcot-Marie-Tooth disease.Muscle Nerve 2006; 34(5): 586-94
119. Bradley WG, Badger GJ, Tandan R, et al.Double-blind controlled trials of Cronassial in chronic neuromuscular diseases and ataxia.Neurology 1988; 38(11): 1731-9